Kymera Therapeutics, Inc. (KYMR) Discusses KT-621 BroADen Phase 1b Results in Atopic Dermatitis - Slideshow (NASDAQ:KYMR) 2025-12-08

Group 1 - The article does not provide any relevant content regarding the company or industry [1]